New Technology to end OI

University of Sheffield

Guest
The 'scaffolding' breakthrough that rebuilds skin for victims of burns and ulcers
By Pat Hagan
Last updated at 11:19 PM on 18th August 2008
A bandage that helps new skin grow, then dissolves safely into the body, could be a major breakthrough in the treatment of burns and ulcers.
The high-tech dressing acts as a type of scaffolding for skin cells to latch on to and grow.
After six to eight weeks, when a patch of new skin tissue has formed, the ultra-fine bandage is harmlessly absorbed into the bloodstream in the same way as dissolvable stitches used to sew up wounds.
The skin cells 'need a relatively uncomplicated scaffolding - it's in their DNA to sort themselves into the right arrangement'
The breakthrough, by a team of scientists at Sheffield University, could help patients with extensive burns that are too large to be repaired with conventional skin grafts taken from other parts of the body or from donors.
Patients with deep ulcers that refuse to heal, usually caused by diabetes-related circulation problems, could also benefit.
The new grow-your-own-skin technique has been under development for several years at the University of Sheffield.
A team of researchers there set about looking for a way to help new skin cells grow sufficiently to cover large areas of damage.
The problems with previous techniques:
Although surgeons often patch up burns using skin grafted from other parts of the body, such as the back or buttocks, in severe cases it is often impossible to harvest enough skin to cover the affected area.
One reason is that with very badly burned bodies, doctors need to replace both the inner layer of skin, called the dermis, and the outer layer, known as the epidermis.
Finding areas of healthy skin that can provide a graft of sufficient depth and breadth can be difficult.
Other options include using skin from deceased donors, which means the patient taking anti-rejection drugs for the rest of their life, or using bovine collagen, a type of fibrous protein found in cow's skin, to cover the burned area. This also carries the risk of rejection.

The new technique:
Although there have been previous attempts to build a 'scaffold' on which the body's own skin cells can flourish, these have had limited success.
The latest technique involves making a bandage so fine it looks and feels like tissue paper but has fibres that are 100 times finer.
To begin with, a chemical called a polymer is exposed to a process called electrospinning. This involves pumping the liquid polymer through an electrostatic field and spinning it at high speed so it turns into a fibre barely visible to the naked eye.
These are knitted together into a type of tissue paper the size and shape of the burned skin.
Doctors then scrape a few skin cells from the patient's arm or leg and place them on the bandage scaffold in the laboratory.
Over the next few weeks, the skin cells grow and spread until they cover most of the scaffold. It is then grafted onto the wound. The bandage slowly disappears, leaving the healthy new skin graft in position.
The technique is still being tested in the lab and has yet to be used on patients. But Professor Tony Ryan, who is leading the project, says the results so far are very promising.
'Previous attempts to find better ways of encouraging skin cell growth have used chemical additives and other elaborate techniques to produce scaffolds - but their success has been limited,' he says.
'We've found that skin cells are actually very smart - it's in their DNA to sort themselves into the right arrangement. They just need a comparatively uncomplicated scaffold to help them grow in a safe, natural way.'
Find this story at www.dailymail.co.uk/health/article-...-breakthrough-rebuilds-skin-burns-ulcers.html
 






The 'scaffolding' breakthrough that rebuilds skin for victims of burns and ulcers
By Pat Hagan
Last updated at 11:19 PM on 18th August 2008
A bandage that helps new skin grow, then dissolves safely into the body, could be a major breakthrough in the treatment of burns and ulcers.
The high-tech dressing acts as a type of scaffolding for skin cells to latch on to and grow.
After six to eight weeks, when a patch of new skin tissue has formed, the ultra-fine bandage is harmlessly absorbed into the bloodstream in the same way as dissolvable stitches used to sew up wounds.
The skin cells 'need a relatively uncomplicated scaffolding - it's in their DNA to sort themselves into the right arrangement'
The breakthrough, by a team of scientists at Sheffield University, could help patients with extensive burns that are too large to be repaired with conventional skin grafts taken from other parts of the body or from donors.
Patients with deep ulcers that refuse to heal, usually caused by diabetes-related circulation problems, could also benefit.
The new grow-your-own-skin technique has been under development for several years at the University of Sheffield.
A team of researchers there set about looking for a way to help new skin cells grow sufficiently to cover large areas of damage.
The problems with previous techniques:
Although surgeons often patch up burns using skin grafted from other parts of the body, such as the back or buttocks, in severe cases it is often impossible to harvest enough skin to cover the affected area.
One reason is that with very badly burned bodies, doctors need to replace both the inner layer of skin, called the dermis, and the outer layer, known as the epidermis.
Finding areas of healthy skin that can provide a graft of sufficient depth and breadth can be difficult.
Other options include using skin from deceased donors, which means the patient taking anti-rejection drugs for the rest of their life, or using bovine collagen, a type of fibrous protein found in cow's skin, to cover the burned area. This also carries the risk of rejection.

The new technique:
Although there have been previous attempts to build a 'scaffold' on which the body's own skin cells can flourish, these have had limited success.
The latest technique involves making a bandage so fine it looks and feels like tissue paper but has fibres that are 100 times finer.
To begin with, a chemical called a polymer is exposed to a process called electrospinning. This involves pumping the liquid polymer through an electrostatic field and spinning it at high speed so it turns into a fibre barely visible to the naked eye.
These are knitted together into a type of tissue paper the size and shape of the burned skin.
Doctors then scrape a few skin cells from the patient's arm or leg and place them on the bandage scaffold in the laboratory.
Over the next few weeks, the skin cells grow and spread until they cover most of the scaffold. It is then grafted onto the wound. The bandage slowly disappears, leaving the healthy new skin graft in position.
The technique is still being tested in the lab and has yet to be used on patients. But Professor Tony Ryan, who is leading the project, says the results so far are very promising.
'Previous attempts to find better ways of encouraging skin cell growth have used chemical additives and other elaborate techniques to produce scaffolds - but their success has been limited,' he says.
'We've found that skin cells are actually very smart - it's in their DNA to sort themselves into the right arrangement. They just need a comparatively uncomplicated scaffold to help them grow in a safe, natural way.'
Find this story at www.dailymail.co.uk/health/article-...-breakthrough-rebuilds-skin-burns-ulcers.html

It will depend how fast you can get this method approved, It will take 2-3 years in the USA. My job is safe for a few more years.
 






It will depend how fast you can get this method approved, It will take 2-3 years in the USA. My job is safe for a few more years.

What a waste of the states taxpayers money : 12 million


Governor Patrick Announces Life Sciences Initiative Victory With
Organogenesis' New Headquarters
Regenerative Medicine leader to expand space and employees in Massachusetts,
encompassing over 250,000 square feet for new global headquarters

CANTON, Mass., April 3, 2008 /PRNewswire/ -- Joined by local officials and
Organogenesis, Inc.'s CEO Geoff MacKay, Governor Deval Patrick announced today
that the Massachusetts-based company, which was once planning to move its
operations outside of the state, is initiating an expansion of its global
headquarters, R&D and manufacturing facilities in Canton.
The Governor's $1 billion Life Sciences Initiative was credited by
Organogenesis, the world's leading regenerative medicine company, as a
deciding factor in the company's decision to remain and expand in
Massachusetts and thereby add hundreds of highly skilled jobs.
"I am pleased that Organogenesis will continue to build its future here in
Massachusetts," said Governor Patrick, "This announcement speaks to our
commitment to the long-term growth of this industry."
The Massachusetts Office of Business Development worked closely with
Organogenesis to create a $12.9 million incentive package. In addition, the
state has facilitated $5 million in low-interest loans for growth initiatives.
The Life Sciences Initiative bill also addresses tax inequalities when
compared with competing states.
"When we first began speaking to the office of Economic Development early
last year, Organogenesis had 200 employees, and today, we have 325 with open
positions for an additional 50 jobs in 2008 -- all of these being high-skilled
positions," said Organogenesis CEO Geoff MacKay. "Driven by both existing
high revenue growth and major regulatory approvals, we are well on target for
doubling our workforce."
"Governor Patrick, Secretary O'Connell as well as House and Senate
leadership, have made a significant commitment to the life sciences sector and
we are pleased to see their efforts coming to fruition," continued MacKay.
"The Life Sciences Initiative bill solidifies the state of Massachusetts as
the best place in the world to translate potentially life saving research into
viable, successful businesses."
Currently located at 150 Dan Road, Canton, the new Organogenesis
headquarters campus comprises three large buildings encompassing more than
250,000 square feet and within 100 yards of each other:
85 Dan Road
-- Corporate offices will occupy this facility
-- 78,000+ square feet, including 40,000 square feet of currently
built-out office space (the remaining space is empty open bay for
expansion)
-- Upgrades may add up to 10,500 square feet to the building footprint


150 Dan Road
-- To become main research and development labs and pilot manufacturing
site for smaller product lines
-- 79,000+ square feet


275 Dan Road
-- To become main manufacturing facility, including 60,000 square feet of
manufacturing and quality labs, as well as shipping/receiving and
other support systems
-- 95,000+ square feet


Founded in 1985 to commercialize technologies initially discovered at the
Massachusetts Institute of Technology (MIT), Canton-based Organogenesis
delivers living cell therapy "on demand" to medical clinics. Organogenesis'
signature product, Apligraf(R), is the first bio-engineered living cell
therapy to have received FDA approvals to close diabetic foot ulcers and
venous leg ulcers.
Unveiled last spring, Governor Patrick's life sciences plan includes a
10-year, $1 billion investment package that will both enhance the
Commonwealth's already nationally recognized assets in the fields of medicine
and science, and fill gaps in federal funding to ensure the state's ability to
support life science progress from the idea stage through the production and
commercialization stages. Key to the Governor's Life Science Initiative is new
legislation that will strengthen the Massachusetts Life Science Center and
charge it with the execution of a life science mission focused on science and
economic development, strategic investments at critical stages of the
development cycle, and collaboration with the private sector to create
innovation infrastructure critical to both researchers and companies.
About Regenerative Medicine
A new frontier in healthcare, regenerative medicine utilizes living human
cells, including stem cells, to repair or replace body tissue damaged by
injury, disease or even the natural aging process.
Regenerative medicine is a multidisciplinary field which brings together
biology, medicine, and engineering to empower scientists to grow living cells,
tissues and organs in the laboratory, and to safely implant them into the
human body for the purposes of healing.
About Organogenesis, Inc.
Massachusetts based Organogenesis, Inc. is the world's most successful
regenerative medicine company and is focused in areas of bio-active wound
healing, bio-surgery and bio-aesthetics. Organogenesis delivers living tissue
"on demand," and its mission is to bring the medical marvel of regenerative
medicine products to patients and to standardize their use in everyday medical
care.
Organogenesis is in the midst of a large expansion, both in the U.S., as
well as overseas. As the world's leading Regenerative Medicine company,
Organogenesis has broadened its international scope and ties over the past few
years. The company has recently established European headquarters located in
Switzerland. In addition, last December the company announced an agreement
with China's National Tissue Engineering Center (NTEC), a leading stem cell
and regenerative medicine consortium, headquartered in Shanghai, for the
commercialization of Organogenesis, Inc. technology within the Chinese market,
and potentially throughout Asia. For more information, visit
www.organogenesis.com.
 






This might be the dumbest post ever. First of all what is the original posters beef with Organogenesis? I can tell you that they are acutley aware that they will not be able to ride out Apligraf for ever. We have many new products in the pipe, being that we figured out a "scaffold" that works and is living almost ten years ago. That puts us way ahead of the game. We are aware of all potential threats to Apligraf in the worldwide market place. The biggest was China, which is why if you read through the previous posts you can see we are working with the Chinease and keeping them very close. Lastly, about the "scaffold" that will end us- forever!! If you read carefully you will see that the real trick to the scaffold is that it is an electrospun polymer seeded with the ptnts own cells. First of all, in the case of acute wound healing and trauma that will work brilliantly. In chronic wounds all research points to the fact that these cells are senecent in form and function and this is one of the many contributors to a lack of wound healing. We have a large cell bank full of highly proliferative neo-natal cells that we can seed on any scaffold we want. We are currently working on our next generation Apligraf that will have only human collagen and no bovine or non-human component to speak of. But, just in case those nice researchers in the UK prove to the world that electrospun polymers and seeded cells is the wave of the future....I'm glad we purchased Nanomatrix a company that is a commercial spin off of VCU in Richmond, one of the foremost universities in electrospinning research.

Maybe you missed this press release while you were searching the pr-wire for predictions of doom-and-gloom for Organogenesis.

"Regenerative Medicine Leader Strengthens Scaffold-Engineering Capabilities
with Electrospinning Platform Technology & Team

CANTON, Mass. and BATON ROUGE, La., Feb. 25 /PRNewswire/ -- Organogenesis,
Inc., the world's most successful regenerative medicine company, announced
today the strategic acquisition of Baton Rouge-based NanoMatrix, Inc.
NanoMatrix's platform technology develops "designer scaffolds" for the
purposes of regenerative medicine, based on the fabrication technique known as
electrospinning. Electrospinning is a novel method of producing and
assembling nano-scale fibers into three-dimensional scaffolds, which mimic the
structure and biochemical environment of the human body's tissues.
NanoMatrix's core technology makes it possible to mimic the three-dimensional
architectural structure that is essential for the body's natural growth and
repair processes.
"This acquisition strengthens Organogenesis' position as the leading
innovator in developing three-dimensional regenerative medicine constructs,"
said Geoff MacKay, CEO of Organogenesis. "The technology platforms of
Organogenesis and NanoMatrix are highly complementary. Our innovative
electrospinning techniques enable researchers to develop the most
cell-friendly scaffolds and physiologically-realistic tissues to date,
translating into greater clinical benefit for the patient."
William C. Fioretti, Ph.D., Chairman of NanoMatrix, said, "We are very
pleased with the acquisition by Organogenesis, which has the team, experience
in cellular therapy, and the vision to maximize the platform technology's
potential. Our technology can be used to have a significant impact on
biomatrix materials and patient care, and this transaction assures that it
will come to market. "
Organogenesis is the first company to successfully mass-produce living
regenerative medicine products, reaching hundreds of thousands of patients.
Its signature product, Apligraf(R), is the first bio-engineered cell therapy
to have received FDA approval, and is used by doctors successfully in treating
patients with diabetic foot ulcers and venous leg ulcers in the U.S. and other
markets across the world.
In addition to acquiring NanoMatrix's platform technology, intellectual
property and commercial-scale equipment, Organogenesis gains NanoMatrix
veteran talent, including Gary Cadd, Ph.D. Gary brings with him more than 17
years of biomaterials research, and has already assembled a team within
Organogenesis' Research & Development department to adapt the technology to
the Company's core business.
Originally developed by scientists at Virginia Commonwealth University,
NanoMatrix's electrospinning capabilities are broad and versatile. Scaffolds
can be fabricated from both natural and synthetic polymers (anything from
collagen to polypropylene) and can even be manufactured into different sizes
and shapes, including tubes, mats and coatings, among others. The fibers
comprising the scaffold can be custom-engineered to a specific orientation
(parallel / perpendicular) or thickness, including on the "nanometer" scale (a
thousand times thinner than a human hair). What results from these
capabilities is an implantable scaffold with the correct fiber diameter,
orientation and architecture, rendered virtually indistinguishable from native
tissue and recognized as "self" by the body.
However, electrospinning is not limited to polymers. Other elements of
regenerative medicine, including cells, drugs and bioactive factors, can be
combined into the scaffold. In fact, electrospinning is an area of intense
focus for academic biomaterials research, validating the importance of this
technology platform. While the collagen nanofiber is the core of NanoMatrix's
proprietary technology, its patents also cover many different synthetic
bioabsorbable polymer types and blends.
"Researchers have used electrospinning techniques to produce a variety of
material, including vascular grafts, nerve guides, tendon and skin," continued
MacKay. "With such expansive capabilities, the list of applicable indications
for electrospinning is vast."
About Regenerative Medicine
A new frontier in healthcare, regenerative medicine is an evolving
therapeutic approach that utilizes living cells to repair or replace body
tissue damaged by injury, disease or the aging process. It is a
multidisciplinary field involving biology, medicine and engineering.
Regenerative therapies rely on the body's own natural ability to repair
and regenerate, and enable the body to heal itself Regenerative medicine also
empowers scientists to grow living cells, tissues and organs in the
laboratory, and to safely implant them into the human body for the purposes of
healing.
About Organogenesis, Inc.
Massachusetts based Organogenesis, Inc. is the world's most successful
regenerative medicine company and is focused in areas of bio-active wound
healing, bio-surgery and bio-aesthetics. Organogenesis delivers living tissue
"on demand," and its mission is to bring the medical marvel of regenerative
medicine products to patients and to standardize their use in everyday medical
care. For more information, visit www.organogenesis.com.
SOURCE Organogenesis, Inc.

Angelyn Lowe of Chase Communications, +1-858-273-1805, alechman@chasepr.com,
for Organogenesis, Inc."
 






Expansion project has been cancelled ?



What a waste of the states taxpayers money : 12 million


Governor Patrick Announces Life Sciences Initiative Victory With
Organogenesis' New Headquarters
Regenerative Medicine leader to expand space and employees in Massachusetts,
encompassing over 250,000 square feet for new global headquarters

CANTON, Mass., April 3, 2008 /PRNewswire/ -- Joined by local officials and
Organogenesis, Inc.'s CEO Geoff MacKay, Governor Deval Patrick announced today
that the Massachusetts-based company, which was once planning to move its
operations outside of the state, is initiating an expansion of its global
headquarters, R&D and manufacturing facilities in Canton.
The Governor's $1 billion Life Sciences Initiative was credited by
Organogenesis, the world's leading regenerative medicine company, as a
deciding factor in the company's decision to remain and expand in
Massachusetts and thereby add hundreds of highly skilled jobs.
"I am pleased that Organogenesis will continue to build its future here in
Massachusetts," said Governor Patrick, "This announcement speaks to our
commitment to the long-term growth of this industry."
The Massachusetts Office of Business Development worked closely with
Organogenesis to create a $12.9 million incentive package. In addition, the
state has facilitated $5 million in low-interest loans for growth initiatives.
The Life Sciences Initiative bill also addresses tax inequalities when
compared with competing states.
"When we first began speaking to the office of Economic Development early
last year, Organogenesis had 200 employees, and today, we have 325 with open
positions for an additional 50 jobs in 2008 -- all of these being high-skilled
positions," said Organogenesis CEO Geoff MacKay. "Driven by both existing
high revenue growth and major regulatory approvals, we are well on target for
doubling our workforce."
"Governor Patrick, Secretary O'Connell as well as House and Senate
leadership, have made a significant commitment to the life sciences sector and
we are pleased to see their efforts coming to fruition," continued MacKay.
"The Life Sciences Initiative bill solidifies the state of Massachusetts as
the best place in the world to translate potentially life saving research into
viable, successful businesses."
Currently located at 150 Dan Road, Canton, the new Organogenesis
headquarters campus comprises three large buildings encompassing more than
250,000 square feet and within 100 yards of each other:
85 Dan Road
-- Corporate offices will occupy this facility
-- 78,000+ square feet, including 40,000 square feet of currently
built-out office space (the remaining space is empty open bay for
expansion)
-- Upgrades may add up to 10,500 square feet to the building footprint


150 Dan Road
-- To become main research and development labs and pilot manufacturing
site for smaller product lines
-- 79,000+ square feet


275 Dan Road
-- To become main manufacturing facility, including 60,000 square feet of
manufacturing and quality labs, as well as shipping/receiving and
other support systems
-- 95,000+ square feet


Founded in 1985 to commercialize technologies initially discovered at the
Massachusetts Institute of Technology (MIT), Canton-based Organogenesis
delivers living cell therapy "on demand" to medical clinics. Organogenesis'
signature product, Apligraf(R), is the first bio-engineered living cell
therapy to have received FDA approvals to close diabetic foot ulcers and
venous leg ulcers.
Unveiled last spring, Governor Patrick's life sciences plan includes a
10-year, $1 billion investment package that will both enhance the
Commonwealth's already nationally recognized assets in the fields of medicine
and science, and fill gaps in federal funding to ensure the state's ability to
support life science progress from the idea stage through the production and
commercialization stages. Key to the Governor's Life Science Initiative is new
legislation that will strengthen the Massachusetts Life Science Center and
charge it with the execution of a life science mission focused on science and
economic development, strategic investments at critical stages of the
development cycle, and collaboration with the private sector to create
innovation infrastructure critical to both researchers and companies.
About Regenerative Medicine
A new frontier in healthcare, regenerative medicine utilizes living human
cells, including stem cells, to repair or replace body tissue damaged by
injury, disease or even the natural aging process.
Regenerative medicine is a multidisciplinary field which brings together
biology, medicine, and engineering to empower scientists to grow living cells,
tissues and organs in the laboratory, and to safely implant them into the
human body for the purposes of healing.
About Organogenesis, Inc.
Massachusetts based Organogenesis, Inc. is the world's most successful
regenerative medicine company and is focused in areas of bio-active wound
healing, bio-surgery and bio-aesthetics. Organogenesis delivers living tissue
"on demand," and its mission is to bring the medical marvel of regenerative
medicine products to patients and to standardize their use in everyday medical
care.
Organogenesis is in the midst of a large expansion, both in the U.S., as
well as overseas. As the world's leading Regenerative Medicine company,
Organogenesis has broadened its international scope and ties over the past few
years. The company has recently established European headquarters located in
Switzerland. In addition, last December the company announced an agreement
with China's National Tissue Engineering Center (NTEC), a leading stem cell
and regenerative medicine consortium, headquartered in Shanghai, for the
commercialization of Organogenesis, Inc. technology within the Chinese market,
and potentially throughout Asia. For more information, visit
www.organogenesis.com.
 


















Listen, I just got a call from A.M. they will be caving some territories in begining this week. Starting with the open ones and determining if they are viable territories. Next week should be some axing.
 






Listen, I just got a call from A.M. they will be caving some territories in begining this week. Starting with the open ones and determining if they are viable territories. Next week should be some axing.

Huh? What the heck is going on? I am so glad that I did not get an offer after all. Whew!!!!
 






s
What a waste of the states taxpayers money : 12 million?


FYI: 12 million dollar payment was denied because OI is a private company and capital is not regulated in privatly held entities. Money can be funneled away by its owners and no one can stop them. I think things will be going very wrong in 2009 for them?



Governor Patrick Announces Life Sciences Initiative Victory With
Organogenesis' New Headquarters
Regenerative Medicine leader to expand space and employees in Massachusetts,
encompassing over 250,000 square feet for new global headquarters

CANTON, Mass., April 3, 2008 /PRNewswire/ -- Joined by local officials and
Organogenesis, Inc.'s CEO Geoff MacKay, Governor Deval Patrick announced today
that the Massachusetts-based company, which was once planning to move its
operations outside of the state, is initiating an expansion of its global
headquarters, R&D and manufacturing facilities in Canton.
The Governor's $1 billion Life Sciences Initiative was credited by
Organogenesis, the world's leading regenerative medicine company, as a
deciding factor in the company's decision to remain and expand in
Massachusetts and thereby add hundreds of highly skilled jobs.
"I am pleased that Organogenesis will continue to build its future here in
Massachusetts," said Governor Patrick, "This announcement speaks to our
commitment to the long-term growth of this industry."
The Massachusetts Office of Business Development worked closely with
Organogenesis to create a $12.9 million incentive package. In addition, the
state has facilitated $5 million in low-interest loans for growth initiatives.
The Life Sciences Initiative bill also addresses tax inequalities when
compared with competing states.
"When we first began speaking to the office of Economic Development early
last year, Organogenesis had 200 employees, and today, we have 325 with open
positions for an additional 50 jobs in 2008 -- all of these being high-skilled
positions," said Organogenesis CEO Geoff MacKay. "Driven by both existing
high revenue growth and major regulatory approvals, we are well on target for
doubling our workforce."
"Governor Patrick, Secretary O'Connell as well as House and Senate
leadership, have made a significant commitment to the life sciences sector and
we are pleased to see their efforts coming to fruition," continued MacKay.
"The Life Sciences Initiative bill solidifies the state of Massachusetts as
the best place in the world to translate potentially life saving research into
viable, successful businesses."
Currently located at 150 Dan Road, Canton, the new Organogenesis
headquarters campus comprises three large buildings encompassing more than
250,000 square feet and within 100 yards of each other:
85 Dan Road
-- Corporate offices will occupy this facility
-- 78,000+ square feet, including 40,000 square feet of currently
built-out office space (the remaining space is empty open bay for
expansion)
-- Upgrades may add up to 10,500 square feet to the building footprint


150 Dan Road
-- To become main research and development labs and pilot manufacturing
site for smaller product lines
-- 79,000+ square feet


275 Dan Road
-- To become main manufacturing facility, including 60,000 square feet of
manufacturing and quality labs, as well as shipping/receiving and
other support systems
-- 95,000+ square feet


Founded in 1985 to commercialize technologies initially discovered at the
Massachusetts Institute of Technology (MIT), Canton-based Organogenesis
delivers living cell therapy "on demand" to medical clinics. Organogenesis'
signature product, Apligraf(R), is the first bio-engineered living cell
therapy to have received FDA approvals to close diabetic foot ulcers and
venous leg ulcers.
Unveiled last spring, Governor Patrick's life sciences plan includes a
10-year, $1 billion investment package that will both enhance the
Commonwealth's already nationally recognized assets in the fields of medicine
and science, and fill gaps in federal funding to ensure the state's ability to
support life science progress from the idea stage through the production and
commercialization stages. Key to the Governor's Life Science Initiative is new
legislation that will strengthen the Massachusetts Life Science Center and
charge it with the execution of a life science mission focused on science and
economic development, strategic investments at critical stages of the
development cycle, and collaboration with the private sector to create
innovation infrastructure critical to both researchers and companies.
About Regenerative Medicine
A new frontier in healthcare, regenerative medicine utilizes living human
cells, including stem cells, to repair or replace body tissue damaged by
injury, disease or even the natural aging process.
Regenerative medicine is a multidisciplinary field which brings together
biology, medicine, and engineering to empower scientists to grow living cells,
tissues and organs in the laboratory, and to safely implant them into the
human body for the purposes of healing.
About Organogenesis, Inc.
Massachusetts based Organogenesis, Inc. is the world's most successful
regenerative medicine company and is focused in areas of bio-active wound
healing, bio-surgery and bio-aesthetics. Organogenesis delivers living tissue
"on demand," and its mission is to bring the medical marvel of regenerative
medicine products to patients and to standardize their use in everyday medical
care.
Organogenesis is in the midst of a large expansion, both in the U.S., as
well as overseas. As the world's leading Regenerative Medicine company,
Organogenesis has broadened its international scope and ties over the past few
years. The company has recently established European headquarters located in
Switzerland. In addition, last December the company announced an agreement
with China's National Tissue Engineering Center (NTEC), a leading stem cell
and regenerative medicine consortium, headquartered in Shanghai, for the
commercialization of Organogenesis, Inc. technology within the Chinese market,
and potentially throughout Asia. For more information, visit
www.organogenesis.com.
 






Geoff "no money for you"

What a waste of the states taxpayers money : 12 million


Governor Patrick Announces Life Sciences Initiative Victory With
Organogenesis' New Headquarters
Regenerative Medicine leader to expand space and employees in Massachusetts,
encompassing over 250,000 square feet for new global headquarters

CANTON, Mass., April 3, 2008 /PRNewswire/ -- Joined by local officials and
Organogenesis, Inc.'s CEO Geoff MacKay, Governor Deval Patrick announced today
that the Massachusetts-based company, which was once planning to move its
operations outside of the state, is initiating an expansion of its global
headquarters, R&D and manufacturing facilities in Canton.
The Governor's $1 billion Life Sciences Initiative was credited by
Organogenesis, the world's leading regenerative medicine company, as a
deciding factor in the company's decision to remain and expand in
Massachusetts and thereby add hundreds of highly skilled jobs.
"I am pleased that Organogenesis will continue to build its future here in
Massachusetts," said Governor Patrick, "This announcement speaks to our
commitment to the long-term growth of this industry."
The Massachusetts Office of Business Development worked closely with
Organogenesis to create a $12.9 million incentive package. In addition, the
state has facilitated $5 million in low-interest loans for growth initiatives.
The Life Sciences Initiative bill also addresses tax inequalities when
compared with competing states.
"When we first began speaking to the office of Economic Development early
last year, Organogenesis had 200 employees, and today, we have 325 with open
positions for an additional 50 jobs in 2008 -- all of these being high-skilled
positions," said Organogenesis CEO Geoff MacKay. "Driven by both existing
high revenue growth and major regulatory approvals, we are well on target for
doubling our workforce."
"Governor Patrick, Secretary O'Connell as well as House and Senate
leadership, have made a significant commitment to the life sciences sector and
we are pleased to see their efforts coming to fruition," continued MacKay.
"The Life Sciences Initiative bill solidifies the state of Massachusetts as
the best place in the world to translate potentially life saving research into
viable, successful businesses."
Currently located at 150 Dan Road, Canton, the new Organogenesis
headquarters campus comprises three large buildings encompassing more than
250,000 square feet and within 100 yards of each other:
85 Dan Road
-- Corporate offices will occupy this facility
-- 78,000+ square feet, including 40,000 square feet of currently
built-out office space (the remaining space is empty open bay for
expansion)
-- Upgrades may add up to 10,500 square feet to the building footprint


150 Dan Road
-- To become main research and development labs and pilot manufacturing
site for smaller product lines
-- 79,000+ square feet


275 Dan Road
-- To become main manufacturing facility, including 60,000 square feet of
manufacturing and quality labs, as well as shipping/receiving and
other support systems
-- 95,000+ square feet


Founded in 1985 to commercialize technologies initially discovered at the
Massachusetts Institute of Technology (MIT), Canton-based Organogenesis
delivers living cell therapy "on demand" to medical clinics. Organogenesis'
signature product, Apligraf(R), is the first bio-engineered living cell
therapy to have received FDA approvals to close diabetic foot ulcers and
venous leg ulcers.
Unveiled last spring, Governor Patrick's life sciences plan includes a
10-year, $1 billion investment package that will both enhance the
Commonwealth's already nationally recognized assets in the fields of medicine
and science, and fill gaps in federal funding to ensure the state's ability to
support life science progress from the idea stage through the production and
commercialization stages. Key to the Governor's Life Science Initiative is new
legislation that will strengthen the Massachusetts Life Science Center and
charge it with the execution of a life science mission focused on science and
economic development, strategic investments at critical stages of the
development cycle, and collaboration with the private sector to create
innovation infrastructure critical to both researchers and companies.
About Regenerative Medicine
A new frontier in healthcare, regenerative medicine utilizes living human
cells, including stem cells, to repair or replace body tissue damaged by
injury, disease or even the natural aging process.
Regenerative medicine is a multidisciplinary field which brings together
biology, medicine, and engineering to empower scientists to grow living cells,
tissues and organs in the laboratory, and to safely implant them into the
human body for the purposes of healing.
About Organogenesis, Inc.
Massachusetts based Organogenesis, Inc. is the world's most successful
regenerative medicine company and is focused in areas of bio-active wound
healing, bio-surgery and bio-aesthetics. Organogenesis delivers living tissue
"on demand," and its mission is to bring the medical marvel of regenerative
medicine products to patients and to standardize their use in everyday medical
care.
Organogenesis is in the midst of a large expansion, both in the U.S., as
well as overseas. As the world's leading Regenerative Medicine company,
Organogenesis has broadened its international scope and ties over the past few
years. The company has recently established European headquarters located in
Switzerland. In addition, last December the company announced an agreement
with China's National Tissue Engineering Center (NTEC), a leading stem cell
and regenerative medicine consortium, headquartered in Shanghai, for the
commercialization of Organogenesis, Inc. technology within the Chinese market,
and potentially throughout Asia. For more information, visit
www.organogenesis.com.
 






Rumor mill:

Has the 275 and 85 expansion project has been halted indefinatly due to the massachusetts life science initiative program being fazed out completely from of all future state budgets?

anyone no if this is true?
 






The state money did not materialize due to burocratic red tape. A minor hurdle for the company that they will most likely overcome. Biggest worries are the two running sales and marketing. You have one that thinks he could create life itself and one that may have trouble understanding this post entirely, (he's on CP more than any rep so I expect he will be one of the first to reply). It's like an Abbott and Costello skit but these two actually despise each other behind each others back.

The rest of the officers are solid, especially the number one and two seats. Just a lack of anyone holding the weak links accountable for their inability and inefficiancies.
 






SAVED BY THE TAX PAYERS AGAIN

The Massachusetts Life Sciences Center agreed yesterday to award a $7.4 million grant to Organogenesis, Inc. to facilitate a major expansion.
The Canton-based regenerative medicine company treats diseases by using living cells to restore damaged tissues and organs.
The grant money will help the company expand its presence in Canton. The company has said that with the expanded location, the company will provide another 280 jobs.
Organogenesis presently employs 200 people.
Also yesterday, the Center appointed three new members to its Scientific Advisory Board. Jonathan Fleming, managing general partner at Oxford Bioscience Partners; Doug Cole, general partner at Flagship Ventures; and Jean M. George, partner at Advanced Technology Ventures, will join the board’s 12 other members in making decisions about the Center’s scientific funding




Rumor mill:

Has the 275 and 85 expansion project has been halted indefinatly due to the massachusetts life science initiative program being fazed out completely from of all future state budgets?

anyone no if this is true?
 






Is this money gone already that we need to lay off people? What happened to all the money?




SAVED BY THE TAX PAYERS AGAIN

The Massachusetts Life Sciences Center agreed yesterday to award a $7.4 million grant to Organogenesis, Inc. to facilitate a major expansion.
The Canton-based regenerative medicine company treats diseases by using living cells to restore damaged tissues and organs.
The grant money will help the company expand its presence in Canton. The company has said that with the expanded location, the company will provide another 280 jobs.
Organogenesis presently employs 200 people.
Also yesterday, the Center appointed three new members to its Scientific Advisory Board. Jonathan Fleming, managing general partner at Oxford Bioscience Partners; Doug Cole, general partner at Flagship Ventures; and Jean M. George, partner at Advanced Technology Ventures, will join the board’s 12 other members in making decisions about the Center’s scientific funding
 






The money was promised. Surely based on that promise it was spent beore the checks were received. Then the funding by the state gets cut due to the current economic status. The money may come eventully but the reality is overspending in light of potential funding has caused a deficit that needs to be recovered.

This link will explain more.
http://www.genomeweb.com/bioregionn...initiatives-program-funding-allowance-second-
 






The 'scaffolding' breakthrough that rebuilds skin for victims of burns and ulcers
By Pat Hagan
Last updated at 11:19 PM on 18th August 2008
A bandage that helps new skin grow, then dissolves safely into the body, could be a major breakthrough in the treatment of burns and ulcers.
The high-tech dressing acts as a type of scaffolding for skin cells to latch on to and grow.
After six to eight weeks, when a patch of new skin tissue has formed, the ultra-fine bandage is harmlessly absorbed into the bloodstream in the same way as dissolvable stitches used to sew up wounds.
The skin cells 'need a relatively uncomplicated scaffolding - it's in their DNA to sort themselves into the right arrangement'
The breakthrough, by a team of scientists at Sheffield University, could help patients with extensive burns that are too large to be repaired with conventional skin grafts taken from other parts of the body or from donors.
Patients with deep ulcers that refuse to heal, usually caused by diabetes-related circulation problems, could also benefit.
The new grow-your-own-skin technique has been under development for several years at the University of Sheffield.
A team of researchers there set about looking for a way to help new skin cells grow sufficiently to cover large areas of damage.
The problems with previous techniques:
Although surgeons often patch up burns using skin grafted from other parts of the body, such as the back or buttocks, in severe cases it is often impossible to harvest enough skin to cover the affected area.
One reason is that with very badly burned bodies, doctors need to replace both the inner layer of skin, called the dermis, and the outer layer, known as the epidermis.
Finding areas of healthy skin that can provide a graft of sufficient depth and breadth can be difficult.
Other options include using skin from deceased donors, which means the patient taking anti-rejection drugs for the rest of their life, or using bovine collagen, a type of fibrous protein found in cow's skin, to cover the burned area. This also carries the risk of rejection.

The new technique:
Although there have been previous attempts to build a 'scaffold' on which the body's own skin cells can flourish, these have had limited success.
The latest technique involves making a bandage so fine it looks and feels like tissue paper but has fibres that are 100 times finer.
To begin with, a chemical called a polymer is exposed to a process called electrospinning. This involves pumping the liquid polymer through an electrostatic field and spinning it at high speed so it turns into a fibre barely visible to the naked eye.
These are knitted together into a type of tissue paper the size and shape of the burned skin.
Doctors then scrape a few skin cells from the patient's arm or leg and place them on the bandage scaffold in the laboratory.
Over the next few weeks, the skin cells grow and spread until they cover most of the scaffold. It is then grafted onto the wound. The bandage slowly disappears, leaving the healthy new skin graft in position.
The technique is still being tested in the lab and has yet to be used on patients. But Professor Tony Ryan, who is leading the project, says the results so far are very promising.
'Previous attempts to find better ways of encouraging skin cell growth have used chemical additives and other elaborate techniques to produce scaffolds - but their success has been limited,' he says.
'We've found that skin cells are actually very smart - it's in their DNA to sort themselves into the right arrangement. They just need a comparatively uncomplicated scaffold to help them grow in a safe, natural way.'
Find this story at www.dailymail.co.uk/health/article-...-breakthrough-rebuilds-skin-burns-ulcers.html

Class 2 RecallApligraf

Date Posted January 24, 2008 Recall Number Z-0675-2008 Product Organogenesis Apligraf, interactive wound and burn dressing, Organogenesis, Inc., Canton, Massachusetts 02021 Code Information Lot Numbers: GS0711.20.01.2A and GS0711.22.01.2A Recalling Firm/Manufacturer Organogenesis, Inc.150 Dan RoadCanton, Massachusetts 02021-2820 For Additional Information Contact Patrick Bilbo781-575-0775
Reason forRecall Contamination: Apligraf units were reported to have contamination in the agarose nutrient medium of some units retained at Organogenesis. Preliminary tests show a gram negative rod (bacillus) organism.
Action On 12/26/07, Organogenesis began to telephone the consignees to inform them of the recall. The firm sent a follow-up fax on 12/31/07 to all treating physicians who applied the product requesting patient status information. The Dear Doctor letter, dated December 27, 2007, was titled, "Subject: Potential contaminated Apligraf Units manufactured by Organogenesis, Inc." Consignees were instructed to return unused product, and monitor patients who received the Apligraf for adverse events. Quantity in Commerce 177 units Distribution Nationwide Distribution.
 












The money was promised. Surely based on that promise it was spent beore the checks were received. Then the funding by the state gets cut due to the current economic status. The money may come eventully but the reality is overspending in light of potential funding has caused a deficit that needs to be recovered.

This link will explain more.
http://www.genomeweb.com/bioregionn...initiatives-program-funding-allowance-second-

I've been taking home some of the spent broth and putting it on my dink at night, it is getting longer and smoother. I am doing my own clinical trials